Counterfeit injectable pens intercepted

The Regional Health Agency (ARS) of Mayotte and the regional customs authority have intercepted several postal shipments containing counterfeit injectable pens, which are typically used for diabetes and obesity treatments. These products pose serious health risks due to their unknown composition and potential dangers.

Health risks of counterfeit medications

The ARS warns that counterfeit injectable pens may not contain the correct medication, may have incorrect dosages, or may include substances with unknown effects. This can lead to ineffective treatment or harmful side effects for users.

Warning against unauthorized purchases

The ARS explicitly advises against buying injectable medications from unauthorized sources such as social networks, unverified websites, or unqualified sellers. Medications should only be obtained through legal prescription and delivery channels, as emphasized by the health agency.

Targeting vulnerable populations

The warning is especially aimed at individuals seeking treatments for diabetes or obesity, who might be tempted by the convenience or perceived effectiveness of these products. The ARS urges people to prioritize safety over ease of access and to avoid using any suspicious injectable pen, even if the packaging looks authentic.

Steps for those who may have used counterfeit pens

For individuals who may have already used a suspicious injectable pen, the ARS recommends contacting a doctor and reporting the product. In case of severe symptoms, emergency services should be contacted immediately by calling 15.

Ongoing monitoring and caution

Authorities are closely monitoring the situation and identifying any new shipments to limit risks to the population. Until more is known, they are urging caution and advising that any injectable medication with uncertain authenticity should not be used without consulting a healthcare professional.